Fundamental Analysis of MoonLake Immunotherapeutics - Growth / Value Index
MLTX - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending up
Tsr Value Index - Poor Score of 23.44
Price to Book Ratio of 4.88 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -11.16 | -42747.51 | -182935.43 % | |
| Price to Book | 4.75 | 3.80 | -77.59 % | 4.51 |
| Price to Sales | 24812258 | 0 | 0 % | |
| Enterprise Value to EBITDA Multiple | 10.17 | -32906.04 | -145570.70 % |
MLTX - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Very Poor Score of 5.00
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | -44.14 | -0.0092 | 99.99 % | -2.55 |
| Return On Asset | -41.55 | -0.0087 | 99.99 % | -2.45 |
| Net Profit Margin | -222372869.74 | 0 | 0 % | 0 |
| Operating Profit Margin | -4933.14 | 0 | 0 % | 0 |
| EBITDA Margin | -222843352.10 | 0 | 0 % | 0 |
Highlights
| Market Cap | 2499.27 M |
| Enterprise Value | -447472.20 M |
| Price/Book TTM | 4.75 |
| Outstanding Share | 62874.60 K |
| Float/ Outstanding Share | 37.32% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | -0.194 |
| Sloan Ratio | 0 |
| Peter Lynch Fair Value | 0 |
MLTX - Growth Highlights
Growth Analysis
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 25.96
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 19738.00 | % | 100.00 % |
| Gross Profit | -19523.00 | 6.47 % | 331.16 % |
| EBITDA | -43984.82 M | 8.53 % | 99.97 % |
| Net Profit | -43891.96 M | 8.60 % | 99.97 % |
| EPS | -3.56 | 99.95 % | NA |
MLTX - Stability Highlights
Stability Analysis
Cash ratio of 51.28
Company financial liquidity has improved
Altman Z Score of -0.191 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0024 | -23.08 % | 0.0024 |
| Cash Ratio | 51.28 | 445.05 % | |
| Quick Ratio | 0 | 0 % | 62.13 |
| Shareholders Equity | 94.14 | 47.94 % | |
| Debt to EBITDA | -26.23 | -852353.32 % |
Historical Valuation Ratios of MoonLake Immunotherapeutics
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of MoonLake Immunotherapeutics
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of MoonLake Immunotherapeutics
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of MoonLake Immunotherapeutics
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)